Form 4: Cadrenal Therapeutics Director Acquires 20,000 Stock Options

A director of Cadrenal Therapeutics, Steven Zelenkofske, has acquired 20,000 stock options, vesting monthly over 12 months starting February 1, 2025.

Summary

• Steven Zelenkofske, a director at Cadrenal Therapeutics, acquired 20,000 stock options on January 23, 2025.
• The options have an exercise price of $19.79.
• These options vest pro rata on a monthly basis over 12 months, commencing on February 1, 2025.
• The options expire on January 22, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants to a director. It is neither particularly positive nor negative, but it does indicate that the director has a vested interest in the company's performance.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who acquire or dispose of company securities. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 12 months is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price of $19.79 is a key factor in determining the value of the options, and it would be compared to the current market price of the stock to assess the potential gain for the director.

Stakeholder Impact

• The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's success.

Key Dates

Keywords

stock options, Cadrenal Therapeutics, director, insider trading, equity, CVKD, vesting